---
figid: PMC10149897__gr6
pmcid: PMC10149897
image_filename: gr6.jpg
figure_link: /pmc/articles/PMC10149897/figure/fig6/
number: Fig. 6
figure_title: ''
caption: (A, B) KEGG prediction of the tryptophan breakdown pathway (A) and tyrosine
  breakdown pathway (B) in the CKD model under BBR intervention (n = 6). (C) KEGG
  prediction of the abundance of TyrB, a key enzyme in the tyrosine metabolism pathway,
  in the CKD model under BBR intervention (n = 6). (D) Molecule docking principle
  between BBR and TyrB and 2D schematic diagram of the binding of BBR to TyrB. (E)
  Correlation of g_Clostridium_sensu_stricto_1 with p-cresol. (F) Correlation of g_Clostridium_sensu_stricto_1
  with p-cresol sulfate. (G) Inhibitory effect of BBR on Clostridium sporogenes (n = 3).
  (H) Inhibitory effect of BBR on Clostridium perfringens (n = 3). The data are shown
  as mean ± S.D., ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
article_title: Berberine ameliorates chronic kidney disease through inhibiting the
  production of gut-derived uremic toxins in the gut microbiota.
citation: Libin Pan, et al. Acta Pharm Sin B. 2023 Apr;13(4):1537-1553.
year: '2023'

doi: 10.1016/j.apsb.2022.12.010
journal_title: Acta Pharmaceutica Sinica. B
journal_nlm_ta: Acta Pharm Sin B
publisher_name: Elsevier

keywords:
- Chronic kidney disease
- Gut microbiota
- Berberine
- Gut–kidney axis
- Clostridium
- p-Cresol
- Uremic toxins
- p-Cresol sulfate

---
